Is C86.61 a billable ICD-10-CM code?

Yes. C86.61 is a billable, specific ICD-10-CM code and is valid for submission on a claim.

Where does C86.61 sit in the tabular list?

Neoplasms (C00-D49), in the block Malignant neoplasms of lymphoid, hematopoietic and related tissue (C81-C96).

C86.61

C86.61 — Primary cutaneous CD30-positive T-cell proliferations, in remission

Billable / specific codeICD-10-CM

C86.61 is a billable, specific ICD-10-CM code for primary cutaneous cd30-positive t-cell proliferations, in remission. It is valid for submission on a claim.

Risk adjustment

C86.61 risk-adjusts. Under the CMS-HCC V28 model it maps to this category:

HCC 20 Lung and Other Severe Cancers1.136 RAF

Coefficient shown for the Community Non-dual Aged segment. A higher HCC in the same hierarchy will suppress this one, so capturing it does not always add score.

Medicare coverage

C86.61 is named in 30 Medicare coverage policies — 30 listing it as supporting medical necessity. Which of them applies to you depends on your Medicare contractor, and coverage genuinely differs by state.

A52450Billing and Coding: Paclitaxel (e.g., Taxol®/Abraxane ™)
A52479Oral Anticancer Drugs - Policy Article
A52479Oral Anticancer Drugs - Policy Article
A52479Oral Anticancer Drugs - Policy Article

Related codes at this level

Codes that share C86.6. If C86.61 is not quite right, the correct code is usually one of these.

C86.60Primary cutaneous CD30-positive T-cell proliferations not having achieved remission

Questions about C86.61

Is C86.61 a billable ICD-10-CM code?: Yes. C86.61 is a billable, specific ICD-10-CM code and is valid for submission on a claim.
Where does C86.61 sit in the tabular list?: Neoplasms (C00-D49), in the block Malignant neoplasms of lymphoid, hematopoietic and related tissue (C81-C96).